U.S. Real-World Evidence (RWE) Solutions Market Worth $2.22 billion by 2029

RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare have been considered to have a positive impact on the U.S. RWE solutions market.